PRKAR1B and neoplasm: Administration of DOPC-PRKAR1B-AS2-siRNA alone or DOPC-control siRNA + cisplatin reduced tumor weight by about 41% (p = 0.09) and 55% (p = 0.03), respectively, compared with DOPC-control siRNA alone.